CLINICAL_TRIALS
trial_result
· 2026-06-12
Clinical Trial Results: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts [Phase 2]
Summary
Phase 2 trial assessing remibrutinib for peanut allergy in adults, reporting efficacy, safety, and tolerability.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Allergy, Peanut | Phase 2 | Status: COMPLETED | Results posted: 2026-06-12